

關注個股 DNM

2020/02/26

Danameco 醫療股份公司


收盤價 14,800

Danameco 醫療股份公司

交易所：HOSE - 行業板塊：醫療設備和業務

個股資料

市值：	65	十億 VND
流通股數：	4,377,605	股
上市日期：	16/02/2011	
國家持有：	9%	
外資持有：	6%	
EPS 基本：	1,984	VND
P/E (TTM)：	7.5x	
P/B (TTM)：	0.7x	
ROE (%)：	10%	
ROA (%)：	5%	
股息比率：	0%	



技術分析

短期阻力關卡：	17.60
短期支撐關卡：	13.94
短期趨勢 (5-10 天)：	上漲
中期阻力關卡：	16.90
中期支撐關卡：	10.10
中期趨勢 (1-3 月)：	下跌

	2016 年	2017 年	2018 年
營收增長	23%	-24%	-5%
稅後利潤增長	0%	-30%	-60%
毛利率	22%	27%	24%
淨利率	7%	6%	3%
EPS 基本	3,168	1,669	-
P/E	4.1x	5.1x	12.8x

同行業公司比較

同行業公司總數: 1

股票編號	市值 (十億 VND)	交易所	毛利 %	D/E	P/E	P/B
DNM	65	HNX	23.6%	2.5%	7.5x	0.7x
MEF	6	UPCOM	0.0%	0.0%	0.2x	0.1x
產業平均			21.6%	2.3%	6.8x	0.7x


DNM - 形成中期反轉模型

股票代碼	DNM
建議價格	14.80
目前價格	14.80
短期趨勢	上漲
中期趨勢	下跌
短期目標	16.90
與目前價格相比的短期上漲空間	14.20%
短期停損	13.94

We Create **Fortune**

Reward/Risk	2.45
預期持有（盤）	13
最佳分配比例	4%

- DNM 是微型資本化股票（仙股-MicroCaps），是屬於醫療設備和業務領域，市值為 590 億越南盾，也是醫療口罩製造企業之一（該行業是在 Corona 病疫中收益良多）。DNM 當前的股票評級為 74 點，表明該股票的中期增長評估為中等，負點是 DNM 的基本水平僅為 56 點，而流行病的“催化劑”在此期間對股價產生積極的影響。
- 自 2020 年 2 月以來，DNM 的流動性有所改善，而該股先前沒有流動性，表明其短期現金流量有所改善。DNM 的短期趨勢從下跌轉為上漲。由於市值，流動性和評級系統中的基本點，我們不建議投資者新購買此股。但是，我們估計該股在短期和中期內的前景非常樂觀。



DNM 股票的價格走勢圖

(* 股票評級 Stock Rating 是企業股票價格基本增長與相對強弱與越南股市三大交易市場剩餘股票相比的相關性比較。想了解更多上市公司的股票水平有關的更多信息，請按下以下鏈接：

<http://stockrating.yuanta.com.vn/>

We Create **Fortune**

短期建議列

股碼	股價	短期趨勢	中期趨勢	建議買進日期	T+交易	短期買進價格	短期停損價格	%利潤	建議	短期風險評估
PPC	27.90	上漲	上漲	7/2/2020	T+13	26.80	26.96	4.10%	持有	低風險
IDJ	16.70	上漲	上漲	7/2/2020	T+13	9.20	12.08	81.52%	持有	低風險
TIG	7.60	上漲	上漲	13/2/2020	T+9	6.40	6.73	18.75%	持有	低風險
VIB	18.00	上漲	上漲	14/2/2020	T+8	18.20	17.71	-1.10%	持有	低風險
TNA	18.40	上漲	下跌	17/2/2020	T+7	19.40	17.61	-5.15%	持有	低風險
CTR	45.40	上漲	上漲	20/2/2020	T+4	48.20	44.29	-5.81%	持有	低風險
IJC	13.30	下跌	下跌	21/2/2020	T+3	14.30	14.48	-6.99%	賣出	高風險

注：

- 高風險：當我們在此水平上進行評估時，投資者應將持股比例停利一半。
- 風險略有增加：投資者可以繼續持有
- 持有並停止購買
- 低風險：投資者可以繼續持有或繼續購買

中等建議清單

目前，我們仍然沒有新的建議。



We Create **Fortune**

元大證券（越南）公司

個人客戶分析部

Nguyễn Thế Minh

研究分析經理

+84 28 3622 6868 ext 3826

minh.nguyen@yuanta.com.vn

Lý Thị Hiền

研究分析主管

+84 28 3622 6868 ext 3908

hien.ly@yuanta.com.vn

Quách Đức Khánh

高級分析專員

+84 28 3622 6868 ext 3833

khanh.quach@yuanta.com.vn

Phạm Tấn Phát

高級分析專員

+84 28 3622 6868 ext 3880

phat.pham@yuanta.com.vn

Nguyễn Trịnh Ngọc Hồng

分析專員

+84 28 3622 6868 ext 3832

hong.nguyen@yuanta.com.vn

個人客戶業務部

Nguyễn Thanh Tùng

總公司業務經理

+84 28 3622 6868 ext 3609

tung.nguyen@yuanta.com.vn

Nguyễn Việt Quang

河內分行經理

+84 28 3622 6868 ext 3404

quang.nguyen@yuanta.com.vn

Võ Thị Thu Thủy

平陽分行經理

+84 28 3622 6868 ext 3505

thuy.vo@yuanta.com.vn

Nguyễn Mạnh Hoạt

堤岸分行經理

+84 28 3622 6868 ext 3847

hoat.nguyen@yuanta.com.vn

Bùi Quốc Phong

同奈分行經理

+84 28 3622 6868

phong.bui@yuanta.com.vn

Chung Kim Hoa

華人客戶部經理

+84 28 3622 6868 ext 3828

hoa.chung@yuanta.com.vn

Đinh Thị Thu Cúc

頭頓分行經理

+84 28 3622 6868 ext 3203

cuc.dinh@yuanta.com.vn

Võ Đình Tuấn

峴港分行經理

+84 28 3622 6868 ext 3301

tuan.vo@yuanta.com.vn

Nguyễn Đức Hoàn

河內南部營業中心經理

+84 28 3622 6868 ext 3409

hoan.nguyen@yuanta.com.vn



We Create Fortune

Appendix A: DN Mortant Disclosures

Analyst Certification

Each research analyst primarily responsible for the content of this research report, in whole or in part, certifies that with respect to each security or issuer that the analyst covered in this report: (1) all of the views expressed accurately reflect his or her personal views about those securities or issuers; and (2) no part of his or her compensation was, is, or will be, directly or indirectly, related to the specific recommendations or views expressed by that research analyst in the research report.

Ratings Definitions

BUY: We have a positive outlook on the stock based on our expected absolute or relative return over the investment period. Our thesis is based on our analysis of the company's outlook, financial performance, catalysts, valuation and risk profile. We recommend investors add to their position.

HOLD-Outperform: In our view, the stock's fundamentals are relatively more attractive than peers at the current price. Our thesis is based on our analysis of the company's outlook, financial performance, catalysts, valuation and risk profile.

HOLD-Underperform: In our view, the stock's fundamentals are relatively less attractive than peers at the current price. Our thesis is based on our analysis of the company's outlook, financial performance, catalysts, valuation and risk profile.

SELL: We have a negative outlook on the stock based on our expected absolute or relative return over the investment period. Our thesis is based on our analysis of the company's outlook, financial performance, catalysts, valuation and risk profile. We recommend investors reduce their position.

Under Review: We actively follow the company, although our estimates, rating and target price are under review.

Restricted: The rating and target price have been suspended temporarily to comply with applicable regulations and/or Yuanta policies.

Note: Yuanta research coverage with a Target Price is based on an investment period of 12 months. Greater China Discovery Series coverage does not have a formal 12 month Target Price and the recommendation is based on an investment period specified by the analyst in the report.

Global Disclaimer

© 2018 Yuanta. All rights reserved. The information in this report has been compiled from sources we believe to be reliable, but we do not hold ourselves responsible for its completeness or accuracy. It is not an offer to sell or solicitation of an offer to buy any securities. All opinions and estimates included in this report constitute our judgment as of this date and are subject to change without notice.

This report provides general information only. Neither the information nor any opinion expressed herein constitutes an offer or invitation to make an offer to buy or sell securities or other investments. This material is prepared for general circulation to clients and is not intended to provide tailored investment advice and does not take into account the individual financial situation and objectives of any specific person who may receive this report. Investors should seek financial advice regarding the appropriateness of investing in any securities, investments or investment strategies discussed or recommended in this report. The information contained in this report has been compiled from sources believed to be reliable but no representation or warranty, express or DNMIed, is made as to its accuracy, completeness or correctness. This report is not (and should not be construed as) a solicitation to act as securities broker or dealer in any jurisdiction by any person or company that is not legally permitted to carry on such business in that jurisdiction.

Yuanta research is distributed in the United States only to Major U.S. Institutional Investors (as defined in Rule 15a-6 under the Securities Exchange Act of 1934, as amended and SEC staff interpretations thereof). All transactions by a US person in the securities mentioned in this report must be effected through a registered broker-dealer under Section 15 of the Securities Exchange Act of 1934, as amended. Yuanta research is distributed in Taiwan by Yuanta Securities Investment Consulting. Yuanta research is distributed in Hong Kong by Yuanta Securities (Hong Kong) Co. Limited, which is licensed in Hong Kong by the Securities and Futures Commission for regulated activities, including Type 4 regulated activity (advising on securities). In Hong Kong, this research report may not be redistributed, retransmitted or disclosed, in whole or in part or and any form or manner, without the express written